Maribavir for Refractory or Resistant Cytomegalovirus Infections in Hematopoietic-cell or Solid-organ Transplant Recipients: A Randomized, Dose-ranging, Double-blind, Phase 2 Study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Maribavir for Refractory or Resistant Cytomegalovirus Infections in Hematopoietic-cell or Solid-organ Transplant Recipients: A Randomized, Dose-ranging, Double-blind, Phase 2 Study

Published:2018-10-16 Issue:8 Volume:68 Page:1255-1264
ISSN:1058-4838
Container-title:Clinical Infectious Diseases
language:en
Short-container-title:

Author:

Papanicolaou Genovefa A¹,Silveira Fernanda P²,Langston Amelia A³,Pereira Marcus R⁴,Avery Robin K⁵,Uknis Marc⁶,Wijatyk Anna⁷,Wu Jingyang⁷,Boeckh Michael⁸,Marty Francisco M⁹,Villano Stephen⁶

Affiliation:

1. Infectious Disease Service, Memorial Sloan Kettering Cancer Center, New York, New York

2. The Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania

3. The Winship Cancer Institute, Atlanta, Georgia

4. Department of Medicine, Columbia University Medical Center, New York, New York

5. Johns Hopkins University, Baltimore, Maryland

6. Shire Pharmaceuticals, Wayne, Pennsylvania

7. Shire Pharmaceuticals, Lexington, Massachusetts

8. The Fred Hutchinson Cancer Research Center, Seattle, Washington

9. Brigham and Women’s Hospital, Boston, Massachusetts

Funder

ViroPharma/Shire Development, LLC

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

Link

http://academic.oup.com/cid/article-pdf/68/8/1255/28272226/ciy706.pdf

Reference34 articles.

1. Outcomes in transplant recipients treated with foscarnet for ganciclovir-resistant or refractory cytomegalovirus infection;Avery;Transplantation,2016

2. Ganciclovir-resistant cytomegalovirus infections among lung transplant recipients are associated with poor outcomes despite treatment with foscarnet-containing regimens;Minces;Antimicrob Agents Chemother,2014

3. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants;Limaye;Lancet,2000

4. Patients with refractory cytomegalovirus (CMV) infection following allogeneic haematopoietic stem cell transplantation are at high risk for CMV disease and non-relapse mortality;Liu;Clin Microbiol Infect,2015

5. Risk factors and outcomes of ganciclovir resistant cytomegalovirus infection in solid organ transplant recipients;Fisher;Clin Infect Dis,2017

Cited by 164 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Maribavir treatment for resistant cytomegalovirus disseminated disease in kidney transplant recipients: A case-based scoping review of real life data in literature;Transplantation Reviews;2024-12

2. Management of cytomegalovirus in adult solid organ transplant patients: GESITRA-IC-SEIMC, CIBERINFEC, and SET recommendations update;Transplantation Reviews;2024-12

3. Cytomegalovirus Retinitis: Clinical Manifestations, Diagnosis and Treatment;Viruses;2024-09-07

4. Management of resistant and refractory cytomegalovirus infections after transplantation;Expert Review of Anti-infective Therapy;2024-09-05

5. A Randomized Controlled Trial Comparing the Tolerability and Efficacy of Maribavir vs. Valganciclovir for CMV Prophylaxis in High-Risk Kidney Transplant Recipients: Study Protocol (Maribavir IIR);2024-09-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3